Moreover, the constructed nanocomposites can realize personalized cancer immunotherapy in combination with anti-PD-1 antibody by integrating tumor-specific antigen to macrophage-derived MPs in addition to HCC therapy. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.